Scaling Success: Vladimir Kochnev’s Approach to Business Growth and Leadership
Kochnev’s leadership extends beyond the wellness industry—his approach to business growth, team empowerment, and market ...
Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (HIMS), Evolent Health (EVH) and Bausch Health Companies (BHC)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Hims & Hers Health (HIMS – Research ...
Medscape7h
Does Taking ‘The Pill’ Reduce Ovarian Cancer Risk?
The researchers found that having ever used oral contraception reduced odds of ovarian cancer by 26% (odds ratio [OR], 0.74; ...
GSK’s Sluggish Shares Seen at Risk of New Activist Campaign
GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks. And with key drug patents set to expire and vaccine ...
businesstech.co.za14h
The man who built one of the world’s biggest pharmaceutical companies in South Africa
Stephen Saad is the CEO of South Africa’s largest pharmaceutical business, Aspen Pharmacare, which has grown into a R75 ...
imt.ie1d
Protecting against RSV – the role of vaccines for young and old
The success of an ongoing pilot programme offering RSV vaccination to newborn infants provides hope in tackling the ...
Ionis Continues to Expand Its Cardiology and Neurology Portfolio, Supporting Narrow Moat
Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...
GlaxoSmithKline (GSK) Gets a Buy from Bernstein
Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.
The Harvard Crimson1d
Biopharma Giant GSK to Expand Research and Development Footprint in Cambridge
International biotechnology company GlaxoSmithKline is moving its vaccine and infectious disease research teams to Cambridge, ...
Gilead Gets FDA Priority Review of Twice-Yearly Shot to Prevent HIV
Gilead Sciences has won Food and Drug Administration priority review for its proposed lenacapavir twice-yearly shot to prevent HIV. Gilead on Tuesday said an FDA green light would make lenacapavir the ...
GSK's Strong Performance: Why I'm Upgrading To 'Strong Buy'
GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...
Business Wire3d
GSK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that GSK plc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has bee ...